Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 first in human clinical trial of nitric oxide for solid tumour

Next Previous
Trial Profile

Phase 1 first in human clinical trial of nitric oxide for solid tumour

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Skin cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 03 Nov 2023 According to a Beyond Cancer media release, additional results from this trial for UNO expected in 2024.
  • 03 Nov 2023 According to a Beyond Cancer media release, results from this trial presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California from November 1st to 5th via a poster presentation of abstract number 733.
  • 19 Apr 2023 According to a Beyond Cancer media release, data is expected later this year. Additional trial sites are being activated throughout Israel to expedite enrollment, increase the diversity of patients, and expand awareness of the safe and effective administration of our UNO technology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top